Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate Generic Rx Bill Would Allow Challenges To “Orange Book” Listings

Executive Summary

The amended version of the McCain/Schumer generic drug legislation would allow generic companies to sue patent holders for not providing correct and complete information about "Orange Book" listings
Advertisement

Related Content

Senate Generic Reform Bill Likely To Result In Earlier ANDA Filings
Bush Generic Rx Proposal Has PhRMA Backing As Alternative To Legislation
Bush Generic Drug Reform Proposal Unlikely To End Push For Legislation
FDA Patent Listing Criteria Allow Polymorph, Product-By-Process Claims
FDA Waxman/Hatch Fix Proposal Is “Beefed-Up” Patent Declarations
House Generic Drug Debate Will Likely Begin With Rep. Thune Bill
Senate Generic Rx Bill Too “One-Sided” For House, GSK Assures Investors
Compromise Medicare Rx Benefit Will Be Next Step For Senate, Daschle Says
“Orange Book” Certifications Would List Patent Claims Under Rockefeller Bill
“Orange Book” Certifications Would List Patent Claims Under Rockefeller Bill
Advertisement
UsernamePublicRestriction

Register

PS040165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel